Companies /Healthcare

Xencor Inc

NASDAQ: XNCR Biotechnology
$33.26
▼ $0.75 (−2.21%) today
Markets closed · 10:09pm ET

XNCR at a Glance

Valuation
Market cap
$2.6B
Profitability
Revenue (TTM)
$200.5M
Profit margin
-58.8%
EPS (TTM)
$-1.56
Price
52-week range
$10 – $41
Street target
$43.83

Headquartered in Pasadena, CA Fiscal year ends December NASDAQ: XNCR xencor.com

About Xencor

Xencor is a clinical-stage biopharmaceutical company that develops engineered antibodies for cancer and autoimmune diseases.

**Technology:** its XmAb engineering technology makes small changes to a protein's structure that create new mechanisms of therapeutic action. The toolkit includes the XmAb 2+1 bispecific format, Xtend half-life extension, Immune Inhibitor Fc domains and the XenLock platform. More than 20 candidates engineered with XmAb technology are in clinical development, and multiple XmAb medicines are marketed by partners.

**Revenue model:** revenue comes from collaborations, milestones and royalties, including royalties from Alexion and Incyte.

**Partnered programs:**
- Amgen's xaluritamig (STEAP1 x CD3) in Phase 3 for metastatic castration-resistant prostate cancer
- Astellas' ASP2138 (CLDN18.2 x CD3) in Phase 3 for gastric/GEJ cancer
- Zenas' obexelimab, under FDA BLA review for IgG4-related disease

**Wholly owned oncology pipeline:**
- XmAb819 (ENPP3 x CD3) for clear cell renal cell carcinoma and other ENPP3+ tumors, headed toward a potential Phase 3
- XmAb541 (CLDN6 x CD3) combined with XmAb808 (B7-H3 x CD28)

**Wholly owned autoimmune and inflammatory pipeline:**
- XmAb942 (anti-TL1A), in a Phase 2b study in ulcerative colitis
- XmAb412 (TL1A x IL23p19)
- Plamotamab (CD20 x CD3) for rheumatoid arthritis
- XmAb657 (CD19 x CD3) Updated

Latest Activity

XNCRXencor
Q3 2026
EPS
$0.50
est -$0.34+$0.84
Revenue
$117M
est $63M+85.0%

The first profitable quarter in years came courtesy of one-time cash: a $52.5 million Alexion settlement payment plus a $25 million Astellas milestone, with another $52.5 million from Alexion due in Q3 2027. That funds the pipeline into 2029, and management now expects XmAb819 to enter a registration-enabling study in advanced kidney cancer by the end of 2027.

Quarterly EPS — reported vs estimate

XNCR Coverage

Frequently Asked Questions

What does Xencor do?

Xencor is a clinical-stage biopharmaceutical company that develops engineered antibodies for cancer and autoimmune diseases. **Technology:** its XmAb engineering technology makes small changes to a protein's structure that create new mechanisms of therapeutic action.

What is the XNCR stock price target?

The Wall Street consensus 12-month price target for XNCR is $43.83.